About PVP Biologics
PVP Biologics is a company based in San Diego (United States) founded in 2015 by Ingrid Swanson Pultz and David Baker was acquired by Takeda in February 2020.. PVP Biologics has raised $35 million across 1 funding round from investors including Takeda Pharmaceuticals. The company has 9 employees as of December 31, 2017. PVP Biologics offers products and services including KumaMax. PVP Biologics operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter San Diego, United States
- Employees 9 as on 31 Dec, 2017
- Founders Ingrid Swanson Pultz, David Baker
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Pvp Biologics, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$35 M (USD)
in 1 rounds
-
Latest Funding Round
$35 M (USD), Series B
Jan 05, 2017
- Investors
-
Employee Count
9
as on Dec 31, 2017
-
Acquired by
Takeda
(Feb 26, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PVP Biologics
PVP Biologics offers a comprehensive portfolio of products and services, including KumaMax. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Oral enzyme that breaks down gluten to alleviate celiac symptoms.
Funding Insights of PVP Biologics
PVP Biologics has successfully raised a total of $35M through 1 strategic funding round. The most recent funding activity was a Series B round of $35 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $35.0M
-
First Round
First Round
(05 Jan 2017)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2017 | Amount | Series B - PVP Biologics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in PVP Biologics
PVP Biologics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Takeda Pharmaceuticals is engaged in developing innovative medicines globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by PVP Biologics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - PVP Biologics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pvp Biologics Comparisons
Competitors of PVP Biologics
PVP Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pvp Biologics
Frequently Asked Questions about PVP Biologics
When was PVP Biologics founded?
PVP Biologics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is PVP Biologics located?
PVP Biologics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is PVP Biologics a funded company?
PVP Biologics is a funded company, having raised a total of $35M across 1 funding round to date. The company's 1st funding round was a Series B of $35M, raised on Jan 05, 2017.
How many employees does PVP Biologics have?
As of Dec 31, 2017, the latest employee count at PVP Biologics is 9.
What does PVP Biologics do?
Founded in 2015 and based in San Diego, United States, PVP Biologics operates in the biologics sector. An oral enzyme therapeutic, KumaMax, is being developed to degrade gluten proteins in the stomach. This approach targets celiac disease, an immune-mediated intestinal disorder triggered by gluten from wheat, rye, or barley. Core activities focus on advancing this treatment for safe gluten digestion in affected individuals.
Who are the top competitors of PVP Biologics?
PVP Biologics's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
What products or services does PVP Biologics offer?
PVP Biologics offers KumaMax.
Who are PVP Biologics's investors?
PVP Biologics has 1 investor. Key investors include Takeda Pharmaceuticals.